{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T02:06:59Z","timestamp":1778810819174,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.clgc.2016.06.014","type":"journal-article","created":{"date-parts":[[2016,6,26]],"date-time":"2016-06-26T05:32:25Z","timestamp":1466919145000},"page":"e25-e31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Association Between Number of Endoscopic Resections and Utilization of Bacillus Calmette-Gu\u00e9rin Therapy for Patients With\u00a0High-Grade, Non\u2013Muscle-Invasive Bladder\u00a0Cancer"],"prefix":"10.1016","volume":"15","author":[{"given":"Andrew T.","family":"Lenis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas M.","family":"Donin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark S.","family":"Litwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher S.","family":"Saigal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan M.","family":"Hanley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Badrinath R.","family":"Konety","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim","family":"Chamie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2016.06.014_bib1","first-page":"2309","article-title":"Urothelial tumors of the bladder","volume":"Volume 3","author":"Wood","year":"2010"},{"key":"10.1016\/j.clgc.2016.06.014_bib2","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1002\/cncr.28147","article-title":"Recurrence of high-risk bladder cancer: a population-based analysis","volume":"119","author":"Chamie","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2016.06.014_bib3","doi-asserted-by":"crossref","first-page":"20e9","DOI":"10.1016\/j.urolonc.2014.08.016","article-title":"Treatment and survival in patients with recurrent high-risk non\u2013muscle-invasive bladder cancer","volume":"33","author":"Chamie","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2016.06.014_bib4","first-page":"1964","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2016.06.014_bib5","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.urology.2005.12.014","article-title":"Can intravesical bacillus Calmette-Gu\u00e9rin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials","volume":"67","author":"Han","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2016.06.014_bib6","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.eururo.2013.05.027","article-title":"Maintenance bacillus Calmette-Gu\u00e9rin treatment of non\u2013muscle-invasive bladder cancer: a critical evaluation of the evidence","volume":"64","author":"Ehdaie","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2016.06.014_bib7","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.1002\/cncr.26198","article-title":"Compliance with guidelines for patients with bladder cancer: variation in the delivery of care","volume":"117","author":"Chamie","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2016.06.014_bib8","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1002\/cncr.25007","article-title":"Patterns of care for early stage bladder cancer","volume":"116","author":"Strope","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2016.06.014_bib9","first-page":"1124","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2016.06.014_bib10","first-page":"2158","article-title":"A\u00a0review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group","volume":"186","author":"Brausi","year":"2011","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2016.06.014_bib11","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/j.1464-410X.2012.11060.x","article-title":"Reported use of intravesical therapy for non\u2013muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Advocacy Network (BCAN) survey","volume":"110","author":"Nielsen","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2016.06.014_bib12","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3109\/21681805.2014.968868","article-title":"Use of bacillus Calmette-Gu\u00e9rin in stage T1 bladder cancer: long-term observation of a population-based cohort","volume":"49","author":"Patschan","year":"2015","journal-title":"Scand J Urol"},{"key":"10.1016\/j.clgc.2016.06.014_bib13","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JOP.2011.000480","article-title":"Adjuvant intravesical bacillus Calmette-Gu\u00e9rin therapy and survival among elderly patients with non\u2013muscle-invasive bladder cancer","volume":"9","author":"Spencer","year":"2013","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.clgc.2016.06.014_bib14","first-page":"2314","article-title":"Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update","volume":"178","author":"Hall","year":"2007","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2016.06.014_bib15","doi-asserted-by":"crossref","first-page":"446","DOI":"10.6004\/jnccn.2013.0059","article-title":"Bladder cancer","volume":"11","author":"Clark","year":"2013","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clgc.2016.06.014_bib16","first-page":"180","article-title":"Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2016.06.014_bib17","first-page":"38","article-title":"Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer","volume":"124","author":"Lamm","year":"1980","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2016.06.014_bib18","first-page":"47","article-title":"Intravesical administration of bacillus\u00a0Calmette-Gu\u00e9rin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial","volume":"69","author":"Pinsky","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.clgc.2016.06.014_bib19","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.eursup.2010.08.005","article-title":"Maintenance bacillus Calmette-Gu\u00e9rin: the standard of care for the prophylaxis and management of intermediate- and high-risk non\u2013muscle-invasive bladder cancer","volume":"9","author":"Lamm","year":"2010","journal-title":"Eur Urol Supplements"},{"key":"10.1016\/j.clgc.2016.06.014_bib20","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0302-2838(03)00357-9","article-title":"Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase II trial","volume":"44","author":"Van der Meijden","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2016.06.014_bib21","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose\u00a0versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2016.06.014_bib22","first-page":"220","article-title":"Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer","volume":"137","author":"Catalona","year":"1987","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2016.06.014_bib23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1464-410X.2007.06912.x","article-title":"The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy","volume":"100","author":"Lambert","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2016.06.014_bib24","first-page":"1296","article-title":"Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?","volume":"166","author":"Herr","year":"2001","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2016.06.014_bib25","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.urolonc.2007.04.005","article-title":"Effect of advanced age on the development of complications from intravesical bacillus Calmette-Gu\u00e9rin therapy","volume":"26","author":"Heiner","year":"2008","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2016.06.014_bib26","first-page":"1634","article-title":"The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy","volume":"175","author":"Joudi","year":"2006","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2016.06.014_bib27","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/MOU.0000000000000088","article-title":"New agents for bacillus Calmette-Gu\u00e9rin\u2013refractory nonmuscle invasive bladder cancer","volume":"24","author":"Ahn","year":"2014","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.clgc.2016.06.014_bib28","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ucl.2013.01.004","article-title":"The costs of non\u2013muscle invasive bladder cancer","volume":"40","author":"James","year":"2013","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.clgc.2016.06.014_bib29","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.eururo.2014.11.031","article-title":"Therapeutic options in high-risk non\u2013muscle-invasive bladder cancer during the current worldwide shortage of bacille Calmette-Gu\u00e9rin","volume":"67","author":"Mostafid","year":"2015","journal-title":"Eur Urol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767316301756?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767316301756?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:28:54Z","timestamp":1761564534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767316301756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S1558767316301756"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2016.06.014","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association Between Number of Endoscopic Resections and Utilization of Bacillus Calmette-Gu\u00e9rin Therapy for Patients With\u00a0High-Grade, Non\u2013Muscle-Invasive Bladder\u00a0Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2016.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}